Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | HCAR3 | P49019 | 7/20 | 0.40 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.39 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24045338 | 0.85 | PSMD14 (0.43) | RORCHPGDPSMD14KDM4EALDH1A1 | |
| SCHEMBL24050520 | 0.83 | HCAR3 (0.40) | RORCHCAR3HCAR2HPGDSLC22A12 | |
| SCHEMBL24045340 | 0.76 | KMT2A (0.36) | — | |
| SCHEMBL26565248 | 0.71 | HPGD (0.34) | HCAR3HCAR2HPGDSLC22A12 | |
| SCHEMBL30314628 | 0.70 | RXRA (0.40) | RORCSLC22A12PDE1APDE1BPDE1C | |
| SCHEMBL24045293 | 0.70 | RXRA (0.40) | RORCSLC22A12PDE1APDE1BPDE1C | |
| SCHEMBL16981827 | 0.70 | RORC (0.73) | RORCSLC22A12 | |
| SCHEMBL24045291 | 0.66 | CYP2C19 (0.41) | KDM4EHSD17B10 | |
| SCHEMBL4432096 | 0.66 | ADORA3 (0.55) | HCAR3HCAR2HPGDPSMD14KDM4E | |
| SCHEMBL29234444 | 0.66 | SLC22A12 (0.44) | RORCHCAR3HCAR2SLC22A12PSMD14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-10-21 | — | — | US | disclosed |
| US-20240059700-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | MERCK SHARP & DOHME LLC (US) | 2023-10-17 | — | — | US | disclosed |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | US | disclosed |
| WO-2021236401-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059700-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | RORC 3548/4885HCAR3 3620/4885HCAR2 1202/4885 |
| US-11787810-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | RORC 3419/4885HCAR3 3369/4885HCAR2 1100/4885 |
| US-12448384-B2 | Diacylglyceride O-acyltransferase 2 inhibitors | DGAT2, DGAT1, ACAT2 | RORC 3419/4885HCAR3 3369/4885HCAR2 1100/4885 |
| US-20210363147-A1 | NOVEL DIACYLGLYCERIDE O-ACYLTRANSFERASE 2 INHIBITORS | DGAT2, DGAT1, ACAT2 | RORC 3548/4885HCAR3 3620/4885HCAR2 1202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.